| Literature DB >> 28729318 |
Daniel Munblit1,2,3, Marina Treneva3,4, Ilya Korsunskiy2, Alan Asmanov4, Alexander Pampura4, John O Warner1,3,5.
Abstract
OBJECTIVES: Food allergy is an increasing burden worldwide and is a common problem within paediatric populations, affecting 5%-8% of children. Anaphylaxis caused by food proteins is a potentially life-threatening condition and all healthcare practitioners should be aware of its recognition and management. Russia is the largest country in Europe but it is still unknown whether physicians are prepared to diagnose and manage food-induced anaphylaxis effectively. We aimed to examine physicians' knowledge of diagnosis and management of food-induced anaphylaxis. SETTING, POPULATION AND OUTCOMES: A survey was designed and published online at VrachiRF.ru website (for registered Russian-speaking practicing physicians). We obtained information on respondents' clinical settings, experience and specialty. Survey questions were based on a characteristic clinical scenario of anaphylaxis due to food ingestion. Outcome measures consisted of correct answers to the anaphylaxis diagnosis and management questions.Entities:
Keywords: anaphylaxis; anaphylaxis knowledge; food-induced anaphylaxis; survey
Mesh:
Substances:
Year: 2017 PMID: 28729318 PMCID: PMC5541513 DOI: 10.1136/bmjopen-2017-015901
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of the survey respondents and non-respondents. *: mean (SD)
| Characteristic | N (%) respondents | N (%) Non-respondents | p Value (X2) |
| Gender | |||
| Male | 44 (15%) | 65 (17%) | |
| Female | 255 (85%) | 325 (83%) | 0.48 |
| Age | 47.7 (10.7)* | 49.0 (9.44)* | 0.06 |
| Specialty | |||
| Paediatrics | 203 (68%) | 205 (53%) | |
| Other | 96 (32%) | 185 (47%) |
|
| Clinical settings | |||
| Primary care | 169 (57%) | 224 (57%) | |
| Secondary care | 67 (22%) | 94 (24%) | |
| Tertiary care | 36 (12%) | 42 (11%) | |
| Private practice only | 27 (9%) | 32 (8%) | 0.92 |
| Clinical experience (years) | |||
| 1–5 | 29 (10%) | 25 (6%) | |
| 6–10 | 31 (10%) | 33 (9%) | |
| 11–15 | 30 (10%) | 54 (14%) | |
| >15 | 209 (70%) | 278 (71%) | 0.17 |
Figure 1Physicians’ choice of adrenalin as a first-line treatment of anaphylaxis. This graph shows proportion of physicians to choose: A) intramuscular epinephrine 1:1000 or B) intramuscular prednisolone as a first-line treatment, depending on their choice of diagnosis.
Respondents answers on anaphylaxis clinical scenario
|
|
|
|
|
| Anaphylaxis | 99 (33) |
|
| Yes | 45 (15) |
| Use adrenalin 1:10 000 intramuscular as a first-line treatment | Yes | 31 (10) |
| Use chloropyramine as a first-line treatment | Yes | 79 (26) |
| Use prednisolone intramuscular as a first-line treatment | Yes | 111 (37) |
| Uses prednisolone intramuscular in addition to other therapy | Yes | 109 (37) |
| Oxygen supply | Yes | 141 (47) |
| Salbutamol inhaler | Yes | 139 (46) |
| Antihistamine (cetirizine) | Yes | 11 (4) |
| Inhaled steroids | Yes | 110 (37) |
|
| Yes | 69 (23) |
| Spirometry | Yes | 199 (67) |
| Chest X-ray | Yes | 144 (48) |
| Skin Prick Test (SPT) or specific immunoglobulin E (sIgE) testing to food allergens | Yes | 213 (71) |
| Specific immunoglobulin G (sIgG) testing to food allergens | Yes | 187 (63) |
| Stool ova and parasite exam | Yes | 96 (32) |
Multivariate predictive model for factors influencing physicians decision on anaphylaxis diagnosis and first-line management choice. Statistically significant difference (p<0.05) appear in bold
| Respondents characteristic | Diagnosed patient with anaphylaxis, % | OR (95% CI) | p Value | Used adrenalin 1:1000 intramuscular, % | OR (95% CI) | p Value | Used prednisolone intramuscular, % | OR (95% CI) | p Value | Used chloropyramine, % | OR (95% CI) | p Value |
|
| 29 | 0.59 (0.36 to 0.98) |
| 13 | 0.68 (0.35 to 1.29) | 0.23 | 41 | 1.60 (0.96 to 2.66) | 0.07 | 27 | 1.18 (0.69 to 2.05 | 0.54 |
|
| 32 | 0.92 (0.50 to 1.69) | 0.79 | 15 | 0.99 (0.45 to 2.20) | 0.99 | 38 | 1.07 (0.60 to 1.91) | 0.83 | 28 | 1.13 (0.60 to 2.12) | 0.71 |
|
| 34 | 1.22 | 0.46 | 16 | 1.36 (0.67 to 2.77) | 0.40 | 39 | 1.36 (0.82 to 2.28) | 0.23 | 29 | 1.43 (0.81 to 2.53) | 0.22 |
|
| 30 | (0.72 to 2.05) | 13 |
Diagnosis and first-line treatment among different respondent groups. X2 test is used for the group comparison. Statistically significant difference (p<0.05) appear in bold
| Anaphylaxis diagnosis OR 95% CI | p Value | Intramuscular adrenalin OR 95% CI | p Value | Prednisolone OR 95% CI | p Value | Chloropyramine OR 95% CI | p Value | |
| Sex | 0.75 (0.36 to 1.57) | 0.45 | 0.71 (0.24 to 2.10) | 0.54 | 1.69 (0.85 to 3.83) | 0.14 | 1.49 (0.70 to 3.15) | 0.30 |
| Age | 0.97 (0.95 to 1.00) | 0.10 | 0.98 (0.94 to 1.03) | 0.42 | 1.00 (0.98 to 1.04) | 0.61 | 0.97 (0.93 to 0.99) |
|
| Specialty | 1.34 (0.77 to 2.35) | 0.31 | 1.30 (0.60 to 2.83) | 0.51 | 1.43 (0.82 to 2.50) | 0.20 | 1.59 (0.85 to 2.97) | 0.15 |
| Clinical settings | 0.51 (0.30 to 0.86) |
| 0.74 (0.36 to 1.50) | 0.40 | 1.55 (0.90 to 2.68) | 0.11 | 0.95 (0.52 to 1.73) | 0.86 |
| Clinical experience | 1.33 (0.59 to 2.99) | 0.49 | 1.39 (0.45 to 4.31) | 0.57 | 0.94 (0.43 to 2.05) | 0.88 | 1.93 (0.81 to 4.61) | 0.14 |
| Anaphylaxis diagnosis | NA | NA | 5.65 (2.81 to 11.36) |
| 0.73 (0.44 to 1.24) | 0.24 | 0.35 (0.19 to 0.67) |
|